Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 825 INDUSTRIAL ROAD, 4TH FLOOR SAN CARLOS CA 94070 |
Tel: | N/A |
Website: | https://www.iovance.com |
IR: | See website |
Key People | ||
Frederick G. Vogt Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary | Jean-Marc Bellemin Chief Financial Officer | Igor P. Bilinsky Chief Operating Officer | Friedrich Graf Finckenstein Chief Medical Officer |
Business Overview |
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company, which commercializes autologous T-cell therapy to address solid tumor cancer. It develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, lifileucel, is being developed in advanced, or metastatic or unresectable, melanoma, as well as in other indications. Lifileucel is investigated in two consecutive cohorts in a clinical trial of advanced melanoma patients post-anti-PD-1 therapy, including in a prospectively defined pivotal cohort. It has initiated Phase III clinical trial of lifileucel in combination with pembrolizumab, TILVANCE-301. The Company is also pursuing registrational strategies for lifileucel in advanced cervical cancer and for its TIL therapy, LN-145, in metastatic non-small cell lung cancer. Its first genetically modified, PD-1 inactivated TIL therapy, IOV-4001, is under Phase I/II clinical trial, IOV-GM1-201. |
Financial Overview |
For the six months ended 30 June 2023, Iovance Biotherapeutics Inc revenues increased from $0K to $238K. Net loss increased 12% to $213.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects focused on developing and commercializing segment loss increase of 20% to $110.1M. |
Employees: | 503 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $879.97M as of Jun 30, 2023 |
Annual revenue (TTM): | $0.24M as of Jun 30, 2023 |
EBITDA (TTM): | -$415.44M as of Jun 30, 2023 |
Net annual income (TTM): | -$418.84M as of Jun 30, 2023 |
Free cash flow (TTM): | -$354.68M as of Jun 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 247,358,979 as of Jul 13, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |